Labcorp Expands Oncology Portfolio
Labcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers to support diagnostic development.
Read MorePosted by Chris Wolski | May 30, 2025 | Cancer |
Labcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers to support diagnostic development.
Read MorePosted by Chris Wolski | May 29, 2025 | Molecular Diagnostics |
NeoGenomics launched its PanTracer Family of genomic profiling tests and Paletrra, an AI-driven spatial proteomics platform.
Read MorePosted by Chris Wolski | May 20, 2025 | Lung Cancer |
The FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read MorePosted by Chris Wolski | May 13, 2025 | Cancer |
Oncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough.
Read MorePosted by Chris Wolski | May 7, 2025 | Cancer |
New predictive algorithms using routine health data and blood tests significantly improve early detection of 15 cancers.
Read More